Dapoxetine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Dapoxetine
| |
| Systematic (IUPAC) name | |
| (1S)-N,N-dimethyl-3-naphthalen-1-yloxy-1-phenyl-propan-1-amine | |
| Identifiers | |
| CAS number | 129938-20-1 (HCl salt) |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | ? |
| Mol. mass | 305.413 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
℞ Prescription only |
| Routes | Oral |
|
WikiDoc Resources for Dapoxetine | |
|
Articles | |
|---|---|
|
Most recent articles on Dapoxetine | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Dapoxetine at Clinical Trials.gov Clinical Trials on Dapoxetine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Dapoxetine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Dapoxetine Discussion groups on Dapoxetine Patient Handouts on Dapoxetine Directions to Hospitals Treating Dapoxetine Risk calculators and risk factors for Dapoxetine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Dapoxetine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: Steven C. Campbell, M.D., Ph.D., Professor of Surgery, Residency Program Director, Section of Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic. You can email Dr. Campbell by clicking here. Office phone: 216-444-5595.
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Dapoxetine is the International Nonproprietary Name of a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. It is currently in Phase III of the approval process.
Function
If approved, this would make Dapoxetine join the ranks of erectile dysfunction drugs such as sildenafil (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®), and some dopamine agonists such as cabergoline (Dostinex®) and pramipexole, as drugs which can be used to improve male sexual health. Misuse of these drugs as aphrodisiacs or sexual enhancers in individuals who do not suffer from sexual health problems is also a possibility and there have been some concerns about doctors being pressured to prescribe such drugs off-label to people who do not actually have a medical need for the drug.
Some research has shown Dapoxetine to have a benefit in the treatment of premature ejaculation.[1]
Approval process
Dapoxetine was created by Eli Lilly and Company and is credited to biochemist David T. Wong. Originally known as LY 210448, it was being developed by Lilly as an antidepressant. Eli Lilly sold the patent to Johnson & Johnson for $65 million dollars and future royalties in December 2003.
Dapoxetine was submitted to the FDA in the form of dapoxetine hydrochloride by the ALZA Corporation and its parent company, Johnson & Johnson for the treatment of premature ejaculation with a New Drug Application (NDA) to the Food and Drug Administration (FDA) on December 28, 2004.
In October of 2005, the FDA issued a "not approvable" letter for dapoxetine.[2]
Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks.
References
- ↑ Safarinejad MR (2007). "Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study". doi:10.1038/sj.npp.1301500. PMID 17625501.
- ↑ http://www.jnj.com/news/jnj_news/20051026_164127.htm
External links
- "PEhomepage.com - treatments for premature ejaculation" - an article on dapoxetine
- "Premature Ejaculation Drug Promising"
- "The many mysteries of the female orgasm" - An editorial about advances in sexual pharmacology
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
